Skip to content

Shreya Goel

Assistant Professor of Molecular Pharmaceutics and Adjunct Assistant Professor of Radiology and Imaging Sciences

Molecular Imaging, Biologics Engineering, Radionuclide therapy, Tumor Microenvironment, Immune Imaging

Shreya Goel

 

Biological Chemistry Program

Education

Ph.D. University of Wisconsin-Madison

 

 

Research

We are a multi-disciplinary group seeking to illuminate drug and disease mechanisms and pharmaceutical delivery through the use of advanced imaging techniques, molecular therapeutics, and combining the two into theranostics. Our current research spans three different but inter-related directions:

  1. We utilize cutting-edge imaging technologies including positron emission tomography and optoacoustic imaging to quantitatively and noninvasively visualize disease microenvironment to develop predictive and response biomarkers.
  2. We apply biochemical strategies to modulate proteins, antibodies and peptides to develop next-generation drug conjugates, with a particular focus on radionuclide therapies.
  3. We apply imaging to determine pharmacokinetics and pharmacodynamics and target engagement of novel therapies to enable evidence-guided rational design and translation of advanced therapies.

Students joining the lab will work in an integrated, collaborative environment with the opportunity to contribute to several high risk- high reward projects at the interface of molecular imaging and therapy. Our lab provides highly interdisciplinary training spanning molecular biology, biochemistry, molecular therapy, radiochemistry and imaging sciences that allow us to make unique, high-impact contributions to cancer therapy.

Please visit our website for more information.

Shreya Goel

 

References

Selected Publications
  1. Singh N, Shi S†, Goel S†. Ultrasmall silica nanoparticles in translational biomedical research: Overview and outlook. Advanced Drug Delivery Reviews, 2023, 192: 114638. (PMID: 36462644)
  2. Goel S†, Shi S†. Promise of hypoxia-targeted tracers in metastatic lymph node imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2022. (PMID: 35994060)
  3. Shi S†, Goel S, Lan X, Cai W. ImmunoPET of CD38 with a radiolabeled nanobody: promising for clinical translation. European Journal of Nuclear Medicine and Molecular Imaging, 2021; 021, 05329. (PMID: 33942140)
  4. Ferreira CA*, Goel S*, Ni D, Ehlerding EB, Rosenkrans ZT, Jiang D, Sun T, Aluicio-Sarduy E, Engle JW, Cai W. Ultrasmall Porous Silica Nanoparticles with Enhanced Pharmacokinetics for Cancer Theranostics. Nano Letters, 2021; 21, 4692. (PMID: 34029471)
  5. Goel S, Zhang G, Dogra P, Nizzero S, Li Z, Cristini V, Wang Z, Shen H, Ferrari M. Sequential deconstruction of multiscale transport of composite drug in metastatic breast cancer. Science Advances, 2020; 6, eaba4498. (PMID: 32637609)
  6. Goel S, England CG, Chen F, Cai W. Positron Emission Tomography and Nanotechnology: A Dynamic Duo for Cancer Theranostics. Advanced Drug Delivery Reviews, 2017;113, 157-176. (PMID: 27521055)
  7. Yu B*, Goel S*, Ni D, Ellison PA, Siamof CM, Jiang D, Cheng L, Kang L, Yu F, Liu Z, Barnhart TE, He Q, Zhang H, Cai W. Reassembly of 89Zr-labeled Cancer Cell Membranes into Multicompartment Membrane-derived Liposomes for PET-trackable Tumor-targeted Theranostics. Advanced Materials, 2018; 30, 1704934. (PMID: 29430735)
  8. Shi S*, Orbay H,* Yang Y, Graves SA, Nayak TR, Hong H, Hernandez R, Luo H, Goel S, Theuer CP, Nickles RJ, Cai W. PET imaging of abdominal aortic aneurysm with 64Cu-Labeled anti-CD105 antibody Fab fragment. Journal of Nuclear Medicine, 2015, 56 (6), 927-932. (PMCID: PMC4452422)
Last Updated: 7/15/25